fashion -WSS

fashion

author：fashion 2025-09-04 02:32:55 - browse：3

Three boxes of Breyanzi on a dark blue background — biotech coverage from STAT — The FDA is looking into adverse events involving a number of CAR-T therapies, including Breyanzi. Illustration: STAT; Source: Business Wire

The Food and Drug Administration said Tuesday that it is investigating whether CAR-T therapy, which uses genetically modified white blood cells to attack tumors, can in rare cases cause lymphoma, a blood cancer.

“Although the overall benefits of these products continue to outweigh their potential risks for their approved uses, FDA is investigating the identified risk of T cell malignancy with serious outcomes, including hospitalization and death, and is evaluating the need for regulatory action,” the agency said in a statement.

The agency noted that it is investigating reports of T cell lymphoma, including cancer cells carrying the engineered T cells, in patients who received CAR-T therapy. Experts in the field, which has produced multiple approved products to treat blood cancer, expressed surprise and puzzlement at the announcement, saying that they had not previously seen data about the risk.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Walensky prepares to leave CDC — and Congress — behind
Next article： Readout Newsletter: Illumina, CRISPR, Regeneron

hotspot

WSS

Palantir health business leans on meeting customers’ needs

Yancopoulos of Regeneron works to expand Dupixent success

Steward Health Care expansion into Malta flopped

Biden launches a new push to limit health care costs

Medicare Advantage insurers pressure Biden for bigger payments

Asbestos ban is immediate, but health effects will linger for decades

entertainment

fashion

focus

Medicare details structure of new drug price negotiation program

Adam's Take: Intra

Moonlake's readout produced a cash windfall. Risks remain

Charles Manson follower Leslie Van Houten released from prison after 53 years

Hollywood unions extend contract negotiations for actors

6 surprising facts about sugar

Trump demands the U.S. pay no more for drugs than other countries … again

Medicare Advantage insurers pressure Biden for bigger payments

After affirmative action ruling, medical educators look to 'holistic review'

Retired US general questions alleged Putin, Prigozhin meeting

focus

Biotech investment managers search for lucrative opportunities

Leqembi, other new Alzheimer’s drugs require better biomarkers

Insurance companies sue energy corporation after it was blamed for helping start Colorado wildfire

Bulgari apologizes to China for listing Taiwan as a country after online backlash

Mirador, a new biotech startup, launches with $400 million

Diabetes management: Digital health tools fall short, study says

hotspot

hotspot

hotspot

leisure time